Episode 287 - RAS in Pancreatic Cancer: The RASolute 302 Study
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Episode 287 - RAS in Pancreatic Cancer: The RASolute 302 Study
-
Narrated by:
-
By:
Chadi is joined by renowned gastrointestinal oncologists, Tanios S. Bekaii-Saab, MD, of Mayo Clinic, and Shubham Pant, MD, MBBS, of MD Anderson Cancer Center, to discuss the groundbreaking findings from the RASolute 302 trial, recently published in The New England Journal of Medicine and presented to a standing ovation during the plenary session at the 2026 ASCO Annual Meeting. Dr. Pant, a study author, provides an insider's perspective on how RAS inhibition is reshaping the treatment landscape for pancreatic cancer, including where these therapies may fit in the current treatment paradigm and how clinicians should manage their unique toxicity profiles. The conversation also looks ahead to the next generation of studies, including RASolute 303 and RASolute 304, and what these trials could mean for the future of precision medicine in pancreatic cancer.
Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. https://www.chadinabhan.com/
Watch all Healthcare Unfiltered episodes on YouTube. https://www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA